- Home
- CRVS vs OPP Comparison
CRVS vs OPP Comparison
Compare CRVS & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- OPP
- Stock Information
- Founded
- CRVS 2014
- OPP 2010
- Country
- CRVS United States
- OPP United States
- Employees
- CRVS N/A
- OPP N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- OPP Finance/Investors Services
- Sector
- CRVS Health Care
- OPP Finance
- Exchange
- CRVS Nasdaq
- OPP Nasdaq
- Market Cap
- CRVS 206.5M
- OPP 204.1M
- IPO Year
- CRVS 2016
- OPP N/A
- Fundamental
- Price
- CRVS $3.61
- OPP $8.42
- Analyst Decision
- CRVS Strong Buy
- OPP
- Analyst Count
- CRVS 3
- OPP 0
- Target Price
- CRVS $16.33
- OPP N/A
- AVG Volume (30 Days)
- CRVS 1.6M
- OPP 108.0K
- Earning Date
- CRVS 05-08-2025
- OPP 01-01-0001
- Dividend Yield
- CRVS N/A
- OPP 14.41%
- EPS Growth
- CRVS N/A
- OPP N/A
- EPS
- CRVS N/A
- OPP N/A
- Revenue
- CRVS N/A
- OPP N/A
- Revenue This Year
- CRVS N/A
- OPP N/A
- Revenue Next Year
- CRVS N/A
- OPP N/A
- P/E Ratio
- CRVS N/A
- OPP N/A
- Revenue Growth
- CRVS N/A
- OPP N/A
- 52 Week Low
- CRVS $1.75
- OPP $7.26
- 52 Week High
- CRVS $10.00
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- CRVS 50.22
- OPP 52.83
- Support Level
- CRVS $3.46
- OPP $8.36
- Resistance Level
- CRVS $4.53
- OPP $8.55
- Average True Range (ATR)
- CRVS 0.28
- OPP 0.12
- MACD
- CRVS 0.02
- OPP 0.02
- Stochastic Oscillator
- CRVS 32.60
- OPP 59.19
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.